Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 09, 2022 at 10:15 pm
Share
Lumosa Therapeutics Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 4.59 million compared to TWD 0.634 million a year ago. Net loss was TWD 154.65 million compared to net income of TWD 468.89 million a year ago. Basic loss per share from continuing operations was TWD 0.95 compared to basic earnings per share from continuing operations of TWD 3.1 a year ago. Diluted loss per share from continuing operations was TWD 0.95 compared to diluted earnings per share from continuing operations of TWD 3.1 a year ago.
For the nine months, sales was TWD 12.29 million compared to TWD 7.3 million a year ago. Net loss was TWD 534.3 million compared to net income of TWD 424.11 million a year ago. Basic loss per share from continuing operations was TWD 3.29 compared to basic earnings per share from continuing operations of TWD 2.83 a year ago. Diluted loss per share from continuing operations was TWD 3.29 compared to diluted earnings per share from continuing operations of TWD 2.82 a year ago.
LUMOSA THERAPEUTICS CO., LTD. is a Taiwan-based company principally engaged in the development of new drugs. The Company is engaged in the development of new drugs for unmet medical needs in the fields of central nervous system (CNS), oncology, and inflammatory diseases. The Company is engaged in scientific licensing and new drug development under the reSEARCH and DEVELOPMENT model.